D

Devyser Diagnostics AB
STO:DVYSR

Watchlist Manager
Devyser Diagnostics AB
STO:DVYSR
Watchlist
Price: 119 SEK 3.48% Market Closed
Market Cap: 2B SEK
Have any thoughts about
Devyser Diagnostics AB?
Write Note

Devyser Diagnostics AB
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Devyser Diagnostics AB
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
D
Devyser Diagnostics AB
STO:DVYSR
Cash Equivalents
kr262.9m
CAGR 3-Years
216%
CAGR 5-Years
103%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Cash Equivalents
kr1.5B
CAGR 3-Years
2%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Cash Equivalents
kr153.2m
CAGR 3-Years
-12%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Cash Equivalents
kr925m
CAGR 3-Years
-42%
CAGR 5-Years
9%
CAGR 10-Years
23%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Cash Equivalents
kr594m
CAGR 3-Years
41%
CAGR 5-Years
-11%
CAGR 10-Years
0%
BioArctic AB
STO:BIOA B
Cash Equivalents
kr611.6m
CAGR 3-Years
-15%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
No Stocks Found

Devyser Diagnostics AB
Glance View

Market Cap
2B SEK
Industry
Biotechnology

Devyser Diagnostics AB engages in the development, manufacture and sale of kits for genetic testing in routine diagnostics. The company is headquartered in Hagersten, Stockholm. The company went IPO on 2021-12-10. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The firm has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The firm provides its products in more than 45 countries.

DVYSR Intrinsic Value
118.6 SEK
Fairly Valued
Intrinsic Value
Price
D

See Also

What is Devyser Diagnostics AB's Cash Equivalents?
Cash Equivalents
262.9m SEK

Based on the financial report for Dec 31, 2023, Devyser Diagnostics AB's Cash Equivalents amounts to 262.9m SEK.

What is Devyser Diagnostics AB's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
103%

Over the last year, the Cash Equivalents growth was -28%. The average annual Cash Equivalents growth rates for Devyser Diagnostics AB have been 216% over the past three years , 103% over the past five years .

Back to Top